Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants

NCT04056117 is registered in ClinicalTrials.gov with LimmaTech Biologics AG as lead sponsor.

NCT NCT04056117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04056117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants
Lead sponsor
LimmaTech Biologics AG
Phase
Phase 1/2
Overall status
Completed
Start date
September 2, 2019
Completion date
November 14, 2022
Enrollment
597 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

shigellosis